Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2020 08:00 ET | Source: Aeterna Zentaris Inc.

AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT

CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 21, 2020 14:00 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market

CHARLESTON, S.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 19, 2020 19:00 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market

CHARLESTON, S.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 12, 2020 08:05 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

CHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), specialty biopharmaceutical company commercializing and developing...
January 28, 2020 08:00 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study P01 final study...
January 27, 2020 08:35 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing...
January 08, 2020 16:01 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC...
December 18, 2019 09:00 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Announces Publication of GHD Management Guidelines

CHARLESTON, S.C., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce that the American Association of Clinical Endocrinologists (AACE) and...
December 16, 2019 09:00 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Announces 2020 Director Changes

CHARLESTON, S.C., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce changes to its director composition planned for the first quarter of 2020....
November 07, 2019 18:28 ET | Source: Aeterna Zentaris Inc.

Aeterna Zentaris Reports Third Quarter 2019 Financial and Operating Results

CHARLESTON, S.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the third quarter ended September 30,...